• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Pal on next steps with cabozantinib/atezolizumab in bladder cancer

Video

Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center, discusses next steps for the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with bladder cancer. At the 2022 ASCO Annual Meeting Pal shared results from the phase 1b COSMIC-021 trial showing promising activity in patients with urothelial carcinoma who had no prior systemic therapy and were cisplatin ineligible; had no prior systemic therapy but were cisplatin eligible, or had received 1 prior immune checkpoint inhibitor, were VEGFR-TKI–naïve, and had received ≤2 lines of therapy overall.

Related Videos
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 2 - "Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC"
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.